RESEARCH MONOGRAPH · KDC-MN-304

Acarbose

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

80/100

The unglamorous alpha-glucosidase inhibitor that the NIA ITP keeps showing extends mouse lifespan, slept-on outside diabetes

Acarbose is a workhorse antidiabetic that's been on the market since 1990 as Precose/Glucobay, and honestly it's one of the most underappreciated longevity research compounds in the field. Mechanism is mechanically simple: it's a competitive inhibitor of intestinal alpha-glucosidase enzymes (sucrase, maltase, glucoamylase) that delays carbohydrate digestion. The result is reduced postprandial glucose excursion at the cost of some carbohydrate maldigestion (the gas, bloating, and flatulence that are the famous tolerability issues).

The clinical diabetes evidence is solid. Acarbose produces modest A1c reductions (around 0.5-0.8 percent), reduces postprandial hyperglycemia substantially, and has been part of the antidiabetic guideline conversation for thirty years. It never became a first-line drug because the GI tolerability and the lifestyle constraint (it needs to be taken with first bite of meals) limited adoption, but the cardiovascular outcomes data from the STOP-NIDDM trial showed reduced incidence of cardiovascular events in pre-diabetic populations, which is more than most antidiabetics can claim.

The longevity research story is what makes acarbose genuinely interesting in our context. The NIA Interventions Testing Program has shown lifespan extension in mice across multiple independent replications, with the effect being more pronounced in males (similar to the 17-alpha-estradiol pattern) and reproducible across multiple sites. The mechanism in mice is presumed to involve reduced caloric absorption and modulated glucose flux, but the gender-specificity and the magnitude of the effect (around 22 percent median lifespan extension in male mice at the higher dose) suggest something more interesting than simple caloric restriction mimetics.

What we like: clean mechanism, decades of human safety data, and a replicated lifespan signal in mice that's about as solid as anything in the longevity field. The cardiovascular outcomes signal in the STOP-NIDDM trial is genuinely interesting.

What we dont love is that the human longevity translation is genuinely uncertain. The mouse data is consistent but the dose-equivalence question is hard, and the GI tolerability ceiling limits how much exposure you can achieve in human use.

Sourcing is excellent. Acarbose is pharma-grade pseudotetrasaccharide, USP-monographed, dirt cheap, and reliably available. HPLC purity is verifiable, the molecule is stable, and the failure modes are minimal. One of the few longevity-research-relevant compounds where the sourcing is genuinely a solved problem.

Evidence: 80
Mechanism: 80
Reliability: 75
Safety: 85
Sourcing: 90
Value: 85
Signal: 70
Staying power: 75

Plain-language summary Intrigue 70 / 100

Acarbose (Precose) is an alpha-glucosidase inhibitor isolated from a soil bacterium and approved in 1996 for type 2 diabetes. It blocks intestinal enzymes that break down complex carbohydrates, slowing carbohydrate absorption and flattening post-meal glucose spikes. Clinically it is a second-tier diabetes drug owing to gastrointestinal side effects (gas, bloating) from undigested carbohydrate fermenting in the colon. The longevity interest comes from the NIA Interventions Testing Program, which reproducibly showed that acarbose extends mouse lifespan, particularly in males, with effects that hold across different diets and genetic backgrounds. The replication is unusually solid for a longevity compound, even if the mouse-to-human translation is uncertain. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Alpha-glucosidase inhibitor

An alpha-glucosidase inhibitor developed for postprandial glucose control in type 2 diabetes; demonstrated lifespan extension in NIA ITP studies.

Abstract

Acarbose (CAS 56180-94-0; pseudotetrasaccharide; molecular formula C25H43NO18; molecular weight 645.60) is an alpha-glucosidase inhibitor isolated from Actinoplanes utahensis and approved by the FDA in 1996 under the trade name Precose. The compound competitively inhibits intestinal alpha-glucosidases (sucrase, maltase, glucoamylase) and pancreatic amylase, delaying complex carbohydrate digestion and producing flatter postprandial glucose curves. Approved for type 2 diabetes mellitus. The longevity application emerged from NIA Interventions Testing Program work demonstrating consistent male mouse lifespan extension; effects are associated with reduced fasting glucose, modified gut microbiome, and possibly mTOR-related pathways. Plasma absorption is minimal (less than 2 percent of oral dose); the principal pharmacology is luminal. Side effects include flatulence and diarrhea (from undigested carbohydrate fermentation in the colon). Used as the canonical alpha-glucosidase inhibitor with lifespan-extension data.

Mechanism of action

Competitive intestinal alpha-glucosidase and pancreatic amylase inhibition; delays complex carbohydrate digestion and flattens postprandial glucose. Lifespan extension in male mice with debated mechanism.

Reported research dose ranges

Clinical 25 to 100 mg in the published literature with each meal. Mouse studies 1000 ppm in food.

References

Harrison DE, et al. Acarbose, 17-alpha-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males. Aging Cell 2014.
van de Laar FA, et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005.
Smith BJ, et al. Acarbose alters gut microbiome and metabolome in mice. JCI Insight 2019.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-304

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Acarbose

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs